The case for early detection and integrated intervention in patients with peripheral arterial disease and intermittent claudication

Journal of Endovascular Therapy

Volumn 10, Issue 3, 2003, Pages 601-613

  Comerota, Anthony J ^a  

^a TOLEDO HOSPITAL   (United States)

Author keywords

Atherosclerosis; Cilostazol; Exercise; Intermittent claudication; Peripheral arterial disease; Pharmacotherapy; Risk factor modification

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; PENTOXIFYLLINE; TICLOPIDINE;

AORTA ATHEROSCLEROSIS; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG MECHANISM; GASTROCNEMIUS MUSCLE; HEADACHE; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIA; KINESIOTHERAPY; LIFESTYLE; MUSCLE EXERCISE; MYALGIA; PATIENT CARE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ARTERIAL OCCLUSIVE DISEASES; HUMANS; INCIDENCE; INTERMITTENT CLAUDICATION; LIFE STYLE; PREVALENCE; RISK FACTORS; TIME FACTORS; VASCULAR SURGICAL PROCEDURES;

EID: 0141813627     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/1545-1550(2003)010<0601:TCFEDA>2.0.CO;2     Document Type: Review

References (66)

1. Hilleman DE. Management of peripheral arterial disease. Am J Health Syst Pharm. 1998;55(19 Suppl 1):S21-S27.
2. Vogt MT, McKenna M, Wolfson SK, et al. The relationship between ankle brachial index, other atherosclerotic disease, diabetes, smoking and mortality in older men and women. Atherosclerosis. 1993;101:191-202.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
4. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2:221-226.
5. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
6. TransAtlantic Inter-Society Consensus. Management of peripheral arterial disease (PAD). TASC Working Group. J Vasc Surg. 2000;31: S77-S96.
7. Hertzer NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984;199:223-233.
8. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47:1255-1256.
9. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172-1181.
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
11. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119-128.
12. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472-1479.
13. Hirsch AT, Halverson SL, Treat-Jacobson D, et al. The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med. 2001;6:87-96.
14. Kannel WB, Skinner JJ, Schwartz MJ, et al. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970;41:875-883.
15. Aquino R, Johnnides C, Makaroun M, et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J Vasc Surg. 2001;34:962-970.
16. Stoffers HE, Kester AD, Kaiser V, et al. Diagnostic value of signs and symptoms associated with peripheral arterial occlusive disease seen in general practice: a multivariable approach. Med Decis Making. 1997;17:61-70.
17. Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81:602-609.
18. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267-275.
19. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942-1947.
20. Lundgren F, Dahllof A-G, Lundholm K, et al. Intermittent claudication-surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann Surg. 1989;209:346-355.
21. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-686.
22. Feigelson HS, Criqui MH, Fronek A, et al. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994;140:526-534.
23. Sakamoto K, Saitoh S, Takagi S, et al. Significance of accumulation of arteriosclerotic risk factors in elderly people: from a study conducted in Tanno-Sobetsz [in Japanese]. Nippon Ronen Igakkai Zasshi. 1998;35:382-388.
24. Fowkes FGR, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135:331-340.
25. Hirsch AT, Treat-Jacobson D, Lando HA, et al. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med. 1997;2:243-251.
26. Katsilambros NL, Tsapogas PC, Arvanitis MP, et al. Risk factors for lower extremity arterial disease in non-insulin-dependent diabetic persons. Diabet Med. 1996;13:243-246.
27. Senti M, Nogues X, Pedro-Botet J, et al. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation. 1992;85:30-36.
28. Valentine RJ, Grayburn PA, Vega GL, et al. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med. 1994;154:801-806.
29. Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med. 1992;232:349-352.
30. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
31. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
32. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
33. Lowe GD, Fowkes FG, Dawes J, et al. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation. 1993;87:1915-1920.
34. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA. 1999;282:2051-2057.
35. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253-260.
36. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983;1:217-219.
37. Karnath B. Smoking cessation. Am J Med. 2002;112:399-405.
38. Skinner JS, Strandness DE. Exercise and intermittent claudication. II. Effect of physical training. Circulation. 1967;36:23-29.
39. Ernst EE, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation. 1987;76:1110-1114.
40. Ruell PA, Imperial ES, Bonar FJ, et al. Intermittent claudication. The effect of physical training on walking tolerance and venous lactate concentration. Eur J Appl Physiol Occup Physiol. 1984;52:420-425.
41. Hiatt WR, Wolfel EE, Meier RH, et al. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994;90:1866-1874.
42. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274:975-980.
43. Regensteiner JG, Meyer TJ, Krupski WC, et al. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology. 1997;48:291-300.
44. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4:297-307.
45. Green RM, McNamara J. The effects of pentoxifylline on patients with intermittent claudication. J Vasc Surg. 1988;7:356-362.
46. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol. 1988;26:569-576.
47. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104:66-72.
48. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996;155:1053-1059.
49. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med. 1990;113:135-146.
50. Incandela L, De Sanctis MT, Cesarone MR, et al. Short-range intermittent claudication and rest pain: microcirculatory effects of pentoxifylline in a randomized, controlled trial. Angiology. 2002;53(Suppl 1):S27-S30.
51. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-2050.
52. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-530.
53. Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg. 1999;178:141-146.
54. Strandness DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002;36:83-91.
55. Data on file. Otsuka America Pharmaceutical. Inc.
56. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
57. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
58. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227:301-308.
59. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998;128:541-544.
60. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.
61. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339.
62. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
63. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597-1603.
64. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126-2132.
65. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-1671.
66. Mehta SR, Yusuf. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol. 2003;41:S79-88.